Department of Otolaryngology-Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Department of Otolaryngology-Head & Neck Surgery, Emory University, Atlanta, Georgia, USA.
Otolaryngol Head Neck Surg. 2022 Feb;166(2):224-232. doi: 10.1177/01945998211011060. Epub 2021 May 11.
To provide a comprehensive state-of-the-art review of the emerging role of urine leukotriene E4 (uLTE4) as a biomarker in the diagnosis of chronic rhinosinusitis (CRS), aspirin-exacerbated respiratory disease (AERD), and asthma.
Ovid MEDLINE(R), Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus.
A state-of-the-art review was performed investigating the role of uLTE4 as a diagnostic biomarker, predictor of disease severity, and potential marker of selected therapeutic efficacy.
uLTE4 has been shown to be a reliable and clinically relevant biomarker for CRS, AERD, and asthma. uLTE4 is helpful in ongoing efforts to better endotype patients with CRS and to predict disease severity.
Aside from being a diagnostic biomarker, uLTE4 is also able to differentiate aspirin-tolerant patients from patients with AERD and has been associated with objective disease severity in patients with CRS with nasal polyposis. uLTE4 levels have also been shown to predict response to medical therapy, particularly leukotriene-modifying agents.
全面综述尿白三烯 E4（uLTE4）作为生物标志物在慢性鼻-鼻窦炎（CRS）、阿司匹林加重性呼吸系统疾病（AERD）和哮喘诊断中的新作用。
Ovid MEDLINE(R)、Ovid EMBASE、Ovid Cochrane 对照试验中心注册库、Ovid Cochrane 系统评价数据库和 Scopus。
对 uLTE4 作为诊断生物标志物、疾病严重程度预测指标以及特定治疗效果潜在标志物的作用进行了全面的综述。
uLTE4 已被证明是 CRS、AERD 和哮喘的可靠且具有临床相关性的生物标志物。uLTE4 有助于进一步对 CRS 患者进行表型分型，并预测疾病严重程度。
除了作为诊断生物标志物外，uLTE4 还能够区分阿司匹林耐受患者和 AERD 患者，并且与伴有鼻息肉的 CRS 患者的客观疾病严重程度相关。uLTE4 水平还可预测药物治疗的反应，尤其是白三烯调节剂。
